logo
Plus   Neg
Share
Email

Merck To Present New And Updated Data On KEYTRUDA, Updated Data On LYNPARZA

Merck (MRK) announced Thursday new and updated data from six abstracts investigating KEYTRUDA (pembrolizumab), the company's anti-PD-1 therapy, as both monotherapy and combination therapy, across a range of difficult-to-treat breast cancers.

The company will present these data at the 2017 San Antonio Breast Cancer Symposium or SABCS from December 5 - 9.

Further, updated data on LYNPARZA (olaparib), the first-in-class poly ADP-ribose polymerase or PARP inhibitor being co-developed and co-commercialized with AstraZeneca, will also be presented.

KEYTRUDA presentations include a Spotlight Session with findings from the phase 2 KEYNOTE-086 trial, Cohort B, investigating KEYTRUDA as a monotherapy in previously untreated patients with metastatic triple-negative breast cancer whose tumors express PD-L1.

Roy Baynes of Merck Research Laboratories said, "We have seen significant therapeutic advances over the years in the field of breast cancer; however, there remains significant unmet medical need, particularly in certain categories of the disease. Through our comprehensive clinical program studying KEYTRUDA, as well as LYNPARZA, we hope to bring additional therapeutic benefit to breast cancer patients."

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Each year, more than eight million children die from preventable diseases in countries with the worst health care systems . Kofi Annan, former head of the UN, said that, "Almost all these deaths will happen in developing countries. A large number of them could be prevented." You do not want to find... As Canada prepares to legalize marijuana nationwide later this year, a national survey by Statistics Canada has thrown up some interesting facts - including that legal marijuana is not a temptation for most Canadians. Regardless of cannabis use, 79 percent of Canadians surveyed said they would not be more likely to try or increase their cannabis consumption just because it is legalized. The Procter & Gamble Company (PG) reported third-quarter net earnings per share of $0.95, an increase of two percent versus the prior year. Net earnings from continuing operations declined 1% year-over-year to $2.54 billion. Core earnings per share increased four percent to $1.00. On average, 20 analysts...
Follow RTT